|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Thrombin Generation (CAT), Single Subject Report
Test Code901667
CPT Codes
85397<br>This test is not available for New York patient testing<br>Restricted Client Code
Preferred Specimen
1 mL plasma collected in a 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.7 mL
Instructions
Collect samples using a 20 gauge needle, do not use a butterfly needle. Samples should be separated within 30 minutes of blood collection as follows: The blood collection tube should be centrifuged at >2000 g for 10 minutes between 18 and 25° C. The plasma should be aspirated by a plastic pipette no less than 1 cm from the buffy coat and transferred
to a plastic tube. The collected plasma should be centrifuged at 10,000 g for another 10 minutes at room temperature (alternatively centrifugation at 2500 g for 20 minutes). Taking care to not disturb the sediment, aspirate the plasma and transfer it into the final transfer vial. Freeze immediately at -70 to -80° C.
to a plastic tube. The collected plasma should be centrifuged at 10,000 g for another 10 minutes at room temperature (alternatively centrifugation at 2500 g for 20 minutes). Taking care to not disturb the sediment, aspirate the plasma and transfer it into the final transfer vial. Freeze immediately at -70 to -80° C.
Transport Container
Transport tube
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 30 days
Refrigerated: Unacceptable
Frozen: 30 days
Methodology
Fluorescence Detection
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon-Fri; Report available: 42 days
Reference Range
See Laboratory Report
Clinical Significance
This method is intended to measure the TF-initiated thrombin generation in human plasma, in the presence of a direct fXa inhibitor (apixaban or rivaroxaban), as a pharmacodynamic (PD) marker to demonstrate the ability of andexanet to reverse the anticoagulant activity of the fXa inhibitors.